Roche welcomes registration of the first subcutaneous PD-L1 cancer immunotherapy

Roche country medical director Richard Woodfield said the registration of TECENTRIQ SC is “a critical step in making this first-in-class anti-PD-L1 formulation available for eligible patients." …